SIRT2 deacylase modulators control B cell metabolic reprogramming in EBV infection and mitogenic activation
Proceedings of the National Academy of Sciences, Volume 123, Issue 35, September 2026. SignificanceEpstein–Barr virus (EBV) causes approximately 200,000 cancer deaths annually, yet therapeutic options remain limited by broad immunosuppression and variable efficacy. We demonstrate that SIRT2 deacylase modulators block EBV-driven B cell ...
We haven't written up this one. PNAS has the full story — the link below goes straight to it.
